Publication:
Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.

dc.contributor.authorProvencio, Mariano
dc.contributor.authorRoyuela, Ana
dc.contributor.authorTorrente, María
dc.contributor.authorPollán, Marina
dc.contributor.authorGómez-Codina, José
dc.contributor.authorSabín, Pilar
dc.contributor.authorLlanos, Marta
dc.contributor.authorGumá, Josep
dc.contributor.authorQuero, Cristina
dc.contributor.authorBlasco, Ana
dc.contributor.authorAguiar, David
dc.contributor.authorGarcía-Arroyo, Francisco Ramón
dc.contributor.authorLavernia, Javier
dc.contributor.authorMartínez, Natividad
dc.contributor.authorMorales, Manuel
dc.contributor.authorSaenz-Cusi, Álvaro
dc.contributor.authorRodríguez, Delvys
dc.contributor.authorCalvo, Virginia
dc.contributor.authorde la Cruz-Merino, Luis
dc.contributor.authorde la Cruz, Miguel Ángel
dc.contributor.authorRueda, Antonio
dc.contributor.authorSpanish Lymphoma Oncology Group
dc.date.accessioned2023-01-25T09:47:25Z
dc.date.available2023-01-25T09:47:25Z
dc.date.issued2017-06-13
dc.description.abstractRelatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex- and age-specific mortality rates in Spain, and OS was compared with age- and sex-matched general population data. A total of 1074 patients with newly diagnosed FL were enrolled. The median OS was 231 months (95% confidence interval [CI], 195-267 months). Event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) were associated with an increased probability of early death, with an SMR of 10.27 (95% CI, 8.26-12.77) for EFS12. The overall SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and it was higher for women (SMR, 3.02; 95% CI, 2.48-3.67) and young adults (SMR, 6.01; 95% CI, 3.13-11.55). More than 10 years after the diagnosis, mortality rates for FL patients were lower than those for the general population (SMR, 0.47; 95% CI, 0.28-0.78). When FL was excluded as a cause of death, the overall SMR was 1.35 (95% CI, 1.11-1.65) without a statistically significant mortality increase in the >60-year-old group in comparison with age- and sex-matched general population data. More than 15% of the patients included in the study (n = 158) had more than 10 years of follow-up. EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population. Cancer 2017;123:3709-3716. © 2017 American Cancer Society.
dc.identifier.doi10.1002/cncr.30795
dc.identifier.essn1097-0142
dc.identifier.pmid28608996
dc.identifier.unpaywallURLhttps://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.30795
dc.identifier.urihttp://hdl.handle.net/10668/11297
dc.issue.number19
dc.journal.titleCancer
dc.journal.titleabbreviationCancer
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Costa del Sol
dc.organizationHospital Universitario Virgen Macarena
dc.page.number3709-3716
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subjectfollicular lymphoma
dc.subjectmortality
dc.subjectstandard mortality ratio
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAntineoplastic Agents
dc.subject.meshCase-Control Studies
dc.subject.meshCause of Death
dc.subject.meshConfidence Intervals
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshLymphoma, Follicular
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshProspective Studies
dc.subject.meshRituximab
dc.subject.meshSex Factors
dc.subject.meshSpain
dc.subject.meshTime Factors
dc.titlePrognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number123
dspace.entity.typePublication

Files